Core Insights - BioCryst Pharmaceuticals announced new data on ORLADEYO (berotralstat) for hereditary angioedema (HAE) treatment to be presented at the EAACI meeting in Glasgow from June 13 to 16, 2025 [1][2][3] Group 1: Presentation Details - Four abstracts will be presented at the EAACI meeting, including a pooled analysis of the APeX-2 and APeX-J trials focusing on the impact of berotralstat on quality of life for HAE patients [1] - A focus group study reported positive perceptions from patients following berotralstat treatment [2] - Interim results from the APeX-P study indicated that berotralstat use reduced the number of HAE attacks requiring treatment in pediatric patients [3] Group 2: Product Information - ORLADEYO (berotralstat) is the first oral therapy specifically designed to prevent HAE attacks in patients aged 12 years and older, functioning as a plasma kallikrein inhibitor [4][5] - The recommended dosage is one capsule per day, with caution advised for dosages higher than 150 mg due to potential QT prolongation [6][7] - The safety and effectiveness of ORLADEYO in pediatric patients under 12 years have not been established, and there is limited data on its use during pregnancy [9][10] Group 3: Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of individuals with hereditary angioedema and other rare diseases, utilizing structure-guided drug design for developing therapeutics [11]